Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Ellodi Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
